Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib Exploratory Study on the Combination of JS014 and Toripalimab in Combination With Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma.

NCT06882876 is registered in ClinicalTrials.gov with Xiangya Hospital of Central South University as lead sponsor.

NCT NCT06882876
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06882876 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib Exploratory Study on the Combination of JS014 and Toripalimab in Combination With Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma.
Lead sponsor
Xiangya Hospital of Central South University
Phase
Phase 1
Overall status
Enrolling by invitation
Start date
July 10, 2025
Completion date
July 30, 2029
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma (hcc)